Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon and Promega Launch Suite of X-MAN Reporter Kits

Published: Monday, March 11, 2013
Last Updated: Monday, March 11, 2013
Bookmark and Share
New kits enable the study of protein characteristics and behaviors at endogenous expression levels.

Horizon Discovery Ltd. (Horizon) and Promega Corporation have announced the launch of a suite of X-MAN™ Reporter Kits. These kits enable researchers, for the first time, to apply functional, cell-based assays that directly interrogate critical biological activities, at endogenous expression levels.

The resulting data is therefore a closer representation of biological disease states.

The X-MAN Reporter Kits are designed for investigation of: protein expression levels, protein localization within a cell, and protein-protein interaction within a molecular pathway, at natural levels of protein and promoter activity.

The kits include genetically-defined reporter cell lines generated using Horizon’s proprietary GENESIS™ gene editing technology with Promega’s innovative and market-leading luminescent and fluorescent reporter technologies.

X-MAN NanoLuc™ Reporter cell lines incorporate Promega’s new NanoLuc Luciferase reporter directly into the native loci of genes of interest, permitting evaluation of genes and proteins at physiologically relevant levels. NanoLuc is the smallest and brightest luciferase reporter available.

X-MAN HaloTag® Reporter cell lines facilitate the introduction of Promega’s HaloTag as an N- or C-terminal fusion to genes encoding proteins of interest at their native genetic loci.

By using different ligands that bind to HaloTag, these cell lines can then be used to look directly at protein localization at endogenous levels including in live cells or to perform protein interaction studies and to capture the protein of interest for further investigation.

Horizon and Promega have also developed X-MAN Glo™ Reporter Kits, which include X-MAN cell lines pre-transfected with Promega’s Firefly Luciferase for in vivo imaging and VivoGlo™ luciferin, provided as isogenic cell lines for experimental control.

These kits enable in vitro experiments to be linked to in vivo imaging through a common parental/mutant cell line pair, leading to improved continuity of findings.

Dr. Paul Morrill, Vice President, Products, Horizon Discovery, said: “Combining Horizon’s X-MAN and GENESIS technologies with Promega’s market-leading reporters has enabled us to create a powerful new suite of tools that allow investigators to study protein expression, interactions, and encoding, at endogenous expression levels. The resulting data sets are more reflective of the biological disease states versus an artefact of the model itself.”

Tom Livelli, Vice President Life Sciences Products and Services, Promega Corporation, commented: “Promega identified Horizon’s GENESIS gene editing technology and X-MAN cell lines as pioneering translational genomics and drug discovery platforms and began working with the Company in 2011. Combined with our world-leading reporter technology, we have created a suite of invaluable tools for the investigation of genetic disease, and the development of new, targeted therapies.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon Launches New E-commerce Platform and Expands UK Headquarters
Key investment includes an integrated web-shop and Enterprise Resource Planning system to support further scale and revenue growth.
Thursday, October 29, 2015
Horizon, Swift Partner on Genomic Reference Standards
Standards to be used to support validation, consistency and accuracy of the panel.
Wednesday, October 28, 2015
Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon Enters Bioproduction Cell Line Licensing Agreement with LakePharma, Inc.
LakePharma to take a full commercial license for GS null CHO K1 cell line from Horizon for improved efficiency in biopharmaceutical manufacturing.
Wednesday, September 16, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
Horizon Discovery Appoints Mr Grahame Cook as a Non-Executive Director
Grahame brings over 20 years’ experience to Horizon.
Thursday, May 14, 2015
Transgenomic to Incorporate Horizon's Genomic Reference Standards
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits.
Thursday, April 23, 2015
Horizon Discovery & Thermo Agreement
Horizon Discovery Group plc and Thermo Fisher Scientific sign supply and commercialization agreement, which will see Thermo market and distribute Horizon’s X-MAN cell line collection.
Monday, April 20, 2015
Horizon and Partners Awarded Up to £6.2M Funding
Horizon to receive up to £652,000 to expand bioproduction research.
Thursday, March 26, 2015
Horizon Discovery Group plc and ArcherDX Sign OEM Agreement
Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers.
Tuesday, March 24, 2015
Horizon Discovery Group plc Named Business of the Year at Business Weekly Awards
Horizon joins select group of companies to receive award for a second time.
Wednesday, March 18, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Group to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Wednesday, March 11, 2015
Horizon Discovery CEO Darrin Disley wins Entrepreneur of the Year
Darrin Disley, CEO of Horizon Discovery, wins Entrepreneur of the Year award at the Quoted Company Awards 2015.
Thursday, January 29, 2015
Horizon Discovery Group plc Trading Update
Revenues expected to be ahead of consensus by approximately 7% driven by an increased global demand for expanded product, service and IP offering.
Monday, January 19, 2015
Scientific News
NASA's DNA Sequencing in Space is a Success
DNA has been sequenced in space for the first time ever for the Biomolecule Sequencer investigation, using the MinION sequencing device.
Molecule Prevents Effect of Chemotherapy
Danish researchers from Aarhus University Hospital and Aarhus University have made a possible breakthrough in the treatment of colorectal cancer.
Tasmanian Devils Evolve To Resist Deadly Cancer
Tasmanian devils are evolving in response to a highly lethal and contagious form of cancer, a Washington State University researcher has found.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Blinding Disease in Canines and Humans Shares Causative Gene, Pathology
Scientists report that they’ve directly compared the disease course between humans and dogs and found remarkable similarities.
Probing How CRISPR-Cas9 Works
New study in Journal of Cell Biology examines DNA targeting dynamics in live cells.
Diagnosing Tumors of Unknown Origin
EPICUP® test is a tool that helps to identify up to 87% of cancers of unknown origin (COD).
Genome Editing Without Cleaving DNA
A team involving Kobe University researchers has succeeded in developing ‘Target-AID’, a genome editing technique that does not cleave the DNA.
New Possibilities Tumor Research
Grazer researchers say gene activity of the tumor from the analysis of circulating DNA in blood ahead.
Controlling Genome Editing with Light
New technique offers precise manipulation of when and where genes are targeted.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!